Health care stocks retreated late Friday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.3%.
The iShares Biotechnology ETF (IBB) was down 0.1%.
In corporate news, Vivos Therapeutics (VVOS) shares jumped 9% after the company said it issued a $1.1 million convertible promissory note to V-Co Investors 2, with proceeds to be used for the acquisition of The Sleep Center of Nevada.
Bicara Therapeutics (BCAX) shares fell 43% after the company said late Thursday that its latest trial for a potential head and neck cancer treatment has yet to reach median overall survival.
Merus (MRUS) shares surged 32% after the company reported favorable interim cancer trial results in the previous day.
Imunon (IMNN) shares rallied 175%. It reported positive data showing an improvement in overall and progression-free survival from a phase 2 trial of IMNN-001 in ovarian cancer.
Fulcrum Therapeutics (FULC) shares gained 5% after Leerink upgraded the stock to outperform from market perform and raised its price target to $12 from $4.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。